Kite Pharma, Inc. KITE announced the initiation of ZUMA-6, a phase Ib/II combination study on its lead pipeline candidate, KTE-C19, in combination Genentech’s Tecentriq (atezolizumab), for the ...

The ZUMA-6 study is a single-arm, open-label, multi-center study. While the phase Ib portion of the study will evaluate the safety of KTE-C19 and atezolizumab given in a sequence, the phase II portion ...